Table 1 Characteristics of enrolled patients
Clinical features | ENPG alone group (n = 20) | Consolidation immunotherapy group (n = 10) | N | % | p-value |
|---|---|---|---|---|---|
Age, n (%) | 1.000 | ||||
≥50 years | 12 | 6 | 18 | 60.0 | |
<50 years | 8 | 4 | 12 | 40.0 | |
Sex, n (%) | 1.000 | ||||
Male | 16 | 8 | 24 | 80.0 | |
Female | 4 | 2 | 6 | 20.0 | |
Body mass index, n (%) | 0.838 | ||||
<18.5 | 2 | 1 | 3 | 10.0 | |
18.5–24.9 | 12 | 7 | 19 | 33.3 | |
>24.9 | 6 | 2 | 8 | 26.7 | |
ICA embolization, n (%) | 1.000 | ||||
Yes | 18 | 9 | 27 | 90.0 | |
No | 2 | 1 | 3 | 10.0 | |
Pathologic type, n (%) | 1.000 | ||||
WHO type II | 12 | 6 | 18 | 60.0 | |
WHO type III | 8 | 4 | 12 | 40.0 | |
Postoperative reconstruction, n (%) | 0.677 | ||||
Septal flap | 7 | 2 | 9 | 30.0 | |
Middle turbinal flap | 1 | 1 | 2 | 13.3 | |
Dural substitute | 2 | 0 | 2 | 6.7 | |
Temporalis muscle flap | 8 | 6 | 14 | 46.7 | |
No use | 2 | 1 | 3 | 10.0 | |
T stage (initial status), n (%) | 0.741 | ||||
T2 | 3 | 2 | 5 | 16.7 | |
T3 | 16 | 8 | 24 | 80.0 | |
T4 | 1 | 0 | 1 | 3.3 | |
T stage (first relapse stauts), n (%) | 1.000 | ||||
T3 | 18 | 9 | 27 | 90.0 | |
T4 | 2 | 1 | 3 | 10.0 | |
Lymph node metastasis, n (%) | 1.000 | ||||
Yes | 6 | 3 | 9 | 30.0 | |
No | 14 | 7 | 21 | 70.0 | |
Period bewteen recurrence and the last session of radiotherapy, n (%) | 1.000 | ||||
≥3 years | 12 | 6 | 18 | 60.0 | |
<3 years | 8 | 4 | 12 | 40.0 | |
Preoperative combined chemotherapy before surgery, n (%) | 0.958 | ||||
Cisplatin | 19 | 9 | 28 | 93.3 | |
Gemcitabine | 12 | 6 | 18 | 60.0 | |
Docetaxel | 7 | 3 | 10 | 33.3 | |
No | 1 | 1 | 2 | 6.7 | |
Recurrence site previously irradiated, n (%) | 0.301 | ||||
Yes | 18 | 10 | 28 | 93.3 | |
No | 2 | 0 | 2 | 6.7 | |
Negative margin, n (%) | - | ||||
Yes | 20 | 10 | 30 | 100.0 | |
No | 0 | 0 | 0 | 0 |